ANHUI ANKE BIOTECHNOLOGY (GROUP) CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.16 CNY | +0.89% |
|
-3.97% | -0.59% |
| Apr. 25 | Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 28 | Anhui Anke Biotechnology Co., Ltd. Proposes Final Dividend for 2023 | CI |
Summary
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -0.59% | 2.35B | D+ | ||
| -2.32% | 90.45B | A- | ||
| +3.68% | 41.45B | A- | ||
| -10.90% | 33.57B | B- | ||
| +58.05% | 25.73B | A | ||
| -19.56% | 14.73B | C | ||
| -9.06% | 12.82B | B- | ||
| -11.34% | 11.7B | D+ | ||
| -43.53% | 11.44B | B | ||
| +3.75% | 8.79B | B+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 300009 Stock
- Ratings Anhui Anke Biotechnology (Group) Co., Ltd.
